No profile data available.
NovoCure Limited (NVCR) is a healthcare company in the targeted healthcare equipment industry, based in Baar, Switzerland, with about 1,605 full-time employees.
It reported revenue of $655.35 million for fiscal year 2025, up 8.3% from fiscal year 2024, and net income of -$136.23 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $183.58 million, up 15.6% from a year before. United States was its largest region in fiscal year 2025, with 59% of revenue. Its market capitalization was $1.70 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
NovoCure reported $655.35 million in revenue for fiscal year 2025, up 8.3% from $605.22 million in fiscal year 2024. In Q2 2026 revenue was $183.58 million.
United States: 59% of revenue by region in fiscal year 2025, followed by Germany (12%).
$1.70 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Axogen, Inc. (AXGN), Inspire Medical Systems, Inc. (INSP), LeMaitre Vascular, Inc. (LMAT), Nolato AB (publ) (NLTBF).